Immunocore (IMCR) announces that the first patient has been treated in the Phase 1/2 trial of its novel ImmTAC candidate, IMC-R117C, targeting PIWIL1 in colorectal and other gastrointestinal cancers. IMC-R117C is Immunocore’s fifth ImmTAC candidate to enter the clinic. PIWIL1 is overexpressed in multiple malignancies, including colorectal cancer, CRC, and is associated with aggressive tumor growth and poor patient survival.i Despite the development and approval of novel therapeutics, there remains a significant unmet medical need in patients with these cancers, especially in advanced colorectal cancer that is refractory to or has relapsed following standard chemotherapies and targeted therapies.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMCR:
- Immunocore downgraded to Equal Weight from Overweight at Morgan Stanley
- Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial
- Immunocore downgraded to Neutral from Outperform at Mizuho
- Immunocore Holdings Prepares Early Loan Agreement Termination
- Immunocore Holdings Plc Reports Strong Q3 Revenue Growth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
